ArticleMolecular therapy oncolytics2020

CXCR4 Antagonist AMD3100 Reverses the Resistance to Tamoxifen in Breast Cancer via Inhibiting AKT Phosphorylation.

Jun Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.